Breaking a three-year silence by the medical and human rights community, a panel of doctors, attorneys, human rights professionals, university professors and ethics experts have called for an investigation into the use of mefloquine on detainees at Guantanamo Naval Prison. The prison camp had instituted in very early 2002 an unprecedented policy of administering full-treatment doses of mefloquine to all incoming detainees at Guantanamo. Complicating the report’s finding was the fact the man who signed off on the mefloquine policy, Captain Albert Shimkus, was also on the task force that investigated the medical ethical issues regarding interrogation that occupied the report.
|By: Jeff Kaye Friday November 15, 2013 2:20 am|
|By: Jeff Kaye Saturday August 20, 2011 6:53 pm|
On August 18, Senator Dianne Feinstein put out a press release indicating that the Department of Defense should consider taking the anti-malarial drug mefloquine, also known as Lariam, out of the DoD drug formulary as it is too dangerous. Feinstein also indicated the drug has been administered to military personnel without the safeguards put in place by a 2009 Department of Defense protocol. But the drug was also used in massive doses on all the Guantanamo detainees, an unprecedented application of the drug on prisoners for supposed preventative purposes.
|By: Jeff Kaye Tuesday August 2, 2011 12:13 am|
In the RT video, Kurnaz talks about his stay in Kandahar, imprisoned by the U.S. military before he was shipped to Guantanamo. He was age 19.
“In Kandahar,” Kurnaz says, “was happening all kinds of things, what you can just imagine under torture. I saw many people get killed under torture in Kandahar.”
|By: Jeff Kaye Wednesday July 20, 2011 8:10 pm|
Australian news sources have announced that the Commonwealth Director of Public Prosecutions (CDPP) have initiated legal actions to seize the royalties former Guantanamo detainee David Hicks has earned from the publication of his autobiography, Guantanamo: My Journey. The book was published last year by Random House Australia, and has reportedly sold upwards of 30,000 copies. No U.S. publisher has bought rights to the book, and it remains unavailable through U.S. booksellers.